ClinicalTrials.gg
CompletedNCT05802914Updated Oct 14, 2026Results posted

Soft Active Back Exosuit to Reduce Workplace Back Pain

An interventional study of Back Exosuit in Low Back Pain, Musculoskeletal Pain and Low Back Injury, sponsored by Wyss Institute at Harvard University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Wyss Institute at Harvard University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 14, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
282nd of 623
97 · median 79
Started
2023
with 22 others
No phase
408 of 712
62 open now
Registered
588th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 282nd largest by enrollment of the 623 interventional ones that give a count, is one of 23 that started in 2023, is one of 408 with no phase, and was the 588th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if a wearable back exosuit can make it safer and easier for workers who bend, lift, and lower objects in an industrial setting.

Many studies have shown that wearable back exoskeletons or exosuits can provide helpful forces making a person's back muscles work less. It is believed that exosuits can lower a person's level of workplace effort and fatigue, making it less likely for them to have back pain at work. Back exosuits could be a solution to make a job easier, but how well they work in the real-world over a long period of time is unclear.

The investigators want to know if workers who wear a back exosuit during the workday will have lower rates of lower back pain or injury than those who are not wearing a back exosuit. The investigators also want to know how well exosuit technology integrates into the workplace (for example, how this technology improves or hinders job performance).

Participants will be randomized into an exosuit group or control group. Participants in the exosuit group will be given a back exosuit that they can use as much as they want at work. All participants will complete surveys monthly.

Researchers will compare the exosuit group to the control group to see if using a back exosuit in a workplace can reduce a person's risk and impact of low back injury or pain. The investigators also want to see if a back exosuit impacts job productivity and if participants find the exosuit becomes useful or bothersome over time.

03

Conditions studied

  • Low Back Pain
  • Musculoskeletal Pain
  • Low Back Injury

Keywords

  • Exoskeleton
  • Ergonomics
  • Wearable Robotics
  • Exosuit
  • Occupational Injury
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years old
  • Works as a full-time (>35 hours/ week) employee for our Industrial Partner
  • Regularly bends, lifts, or lowers objects below hip height >50% of their working day for multiple periods lasting more than 1 hour without sitting
  • Can read and speak in English
  • Has internet access
  • Has completed an Exosuit Shift Demonstration
  • Thigh circumference is > 19" and \< 32"
  • Back length (Neck to Iliac Crest) is >18"

Exclusion criteria

Exclusion Criteria:

  • Temporary workers not directly employed by our Industrial Partner
  • Diagnosed or self-reported sensory motor disorders (stroke, Parkinson's disease, ALS, multiple sclerosis, spinal cord injury, etc.)
  • Use of a pacemaker or other powered, implanted medical devices
  • Medical condition that would make the participant likely to break bones (i.e., osteoporosis or osteopenia)
  • Spinal fracture in the past 2 years
  • Spinal surgery at multiple vertebral levels in the participant's lifetime, including vertebroplasty but excluding injections, such as , nerve blockers, etc.
  • Sought medical care for spinal surgery at a single vertebral level in the past 2 years, including vertebroplasty but excluding injections, such as steroids, nerve blockers, etc.
  • Current malignant cancer
  • Currently pregnant
  • Skin issues / sensitivity that an exosuit could exacerbate (e.g., thin skin, sensitive skin, easy rashing, easy bruising or skin conditions, Epidermolysis Bullosa, etc.)
  • A current episode of upper back or neck pain, requiring modified duties at work
  • A recent episode of LBP resulting in pain (sharp, shooting, burning), radiating below one or both legs (past mid-thigh) in the last 3 months (e.g., sciatica)
  • A recent episode of back pain resulting in time off work, modified duties, or seeking medical attention in the last 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Exosuit

    Exosuit refers to a soft active back exosuit. Participants in the exosuit arm will be fitted to a personal back exosuit device. Participants will be trained on how to use the device (retrieval, donning, powering up, mode switching, and doffing). Participants will be instructed to use the device at work, emphasizing they wear it whenever it seems practical (e.g. lifting) for as long as it remains comfortable. Associates from Verve Motion will check in with exosuit participants to address comfort issues and help participants integrate the exosuit into their workday.

    Device: Back Exosuit

  • No intervention
    Control

    Control participants will not be assigned a back exosuit. Participants in the control group will perform workplace tasks as normal, completing study surveys at baseline and monthly for 4 months that are identical to exosuit group.

Interventions

  • DeviceBack Exosuit

    The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.

    Also known as: Verve SafeLift Suit

06

What researchers measure

Primary outcomes

  1. Level of Work-interfering Low Back Pain (Changes Over Time and Differences Between Groups)

    The Cornell Musculoskeletal Discomfort Questionnaire (MDQ) is a composite score that ranges from 0-90. The score is calculated by multiplying a perceived rating frequency, severity, and work interference of body discomfort with higher scores corresponding to higher overall discomfort. The back discomfort score will be evaluated between the 2 groups at 5 time points.

    Time frame: Baseline, Months (1-4)

  2. Self-reported Incidence of Low Back Pain (Changes Over Time and Differences Between Groups)

    The incidence of a workplace low back discomfort event was defined as a \> 6-point increase in a participant's lower back MDQ (reference in outcome 1) relative to their last recorded survey. If an incidence of low back discomfort is recorded the affirmative status is carried forward into subsequent completed surveys.

    Time frame: Months (1-4)

Secondary outcomes

  1. Self-reported Severity of Low Back Pain (Changes Over Time and Differences Between Groups)

    Back pain severity refers to the level of intensity and the occupational or medical consequence of back pain. The following self-report measures will determine these values. Numerical rating scale of back pain, which ranges from 0-10 where the highest score 10 represents a participants worst pain imaginable.

    Time frame: Baseline, Months (1-4)

  2. Self-reported Intensity of Global Pain (Changes Over Time and Differences Between Groups)

    Beyond low back pain, participants will report on total body discomfort and the intensity of discomfort at various joints: Total body discomfort and interference will be evaluated using the Pain, Enjoyment of Lift and General Activity (PEG) 3 Scale, which ranges from 0-10. A higher score indicates greater pain intensity and greater interference with enjoyment of life and everyday activity.

    Time frame: Baseline, Months (1-4)

  3. Self-reported Intensity of Localized Body Discomfort (Changes Over Time and Differences Between Groups)

    The Cornell MSD scale (reference in outcome 1) will also be evaluated at every other body part (for example, ankles, knees, hip, upper back, neck, shoulders, elbows, and wrists). The composite score represents the sum (total) of all scores across 9 body parts, and ranges from 0-810. A higher score indicates higher intensity, and frequency of work interfering discomfort for multiple body parts.

    Time frame: Baseline, Months (1-4)

  4. Self-reported Perception of Effort (Changes Over Time and Differences Between Groups)

    A modified BORG scale has been developed with questions focusing on perceived level of back exertion. The scale ranges from 0-100, where a higher score indicates higher perceived back effort (maximal effort).

    Time frame: Baseline, Months (1-4)

  5. Self-reported Perception of Physical Fatigue (Changes Over Time and Differences Between Groups)

    A modified BORG scale has been developed with questions focusing on perceived level of workplace fatigue. The scale ranges from 0-100, where a higher score indicates higher perceived physical fatigue (absolutely exhausted).

    Time frame: Baseline, Months 1-4

07

Results

Posted Oct 14, 2026
Limitations and caveats
The study enrolled fewer participants than originally planned, and there was loss to follow-up over the study period. Additionally, most outcomes were self-reported and may be subject to reporting bias. These factors should be considered when interpreting the study findings.

Participant flow

Participant flow — Overall Study
MilestoneExosuitControl
Started6431
Completed4626
Not completed185

Outcome measures

PrimaryLevel of Work-interfering Low Back Pain (Changes Over Time and Differences Between Groups)

The Cornell Musculoskeletal Discomfort Questionnaire (MDQ) is a composite score that ranges from 0-90. The score is calculated by multiplying a perceived rating frequency, severity, and work interference of body discomfort with higher scores corresponding to higher overall discomfort. The back discomfort score will be evaluated between the 2 groups at 5 time points.

Time frame:
Baseline, Months (1-4)
Reported as:
Mean · Scores on a scale
Level of Work-interfering Low Back Pain (Changes Over Time and Differences Between Groups)
Scores on a scaleExosuitControl
Baseline2.1 ± 4.52.5 ± 4.6
Survey 11.2 ± 3.02.5 ± 5.6
Survey 21.3 ± 2.83.1 ± 8.3
Survey 31.0 ± 3.02.0 ± 4.5
Survey 42.0 ± 4.43.2 ± 8.2
PrimarySelf-reported Incidence of Low Back Pain (Changes Over Time and Differences Between Groups)

The incidence of a workplace low back discomfort event was defined as a \> 6-point increase in a participant's lower back MDQ (reference in outcome 1) relative to their last recorded survey. If an incidence of low back discomfort is recorded the affirmative status is carried forward into subsequent completed surveys.

Time frame:
Months (1-4)
Reported as:
Count of participants · Participants
Self-reported Incidence of Low Back Pain (Changes Over Time and Differences Between Groups)
ParticipantsExosuitControl
Survey 111
Survey 223
Survey 324
Survey 436
SecondarySelf-reported Severity of Low Back Pain (Changes Over Time and Differences Between Groups)

Back pain severity refers to the level of intensity and the occupational or medical consequence of back pain. The following self-report measures will determine these values. Numerical rating scale of back pain, which ranges from 0-10 where the highest score 10 represents a participants worst pain imaginable.

Time frame:
Baseline, Months (1-4)
Reported as:
Mean · Scores on a scale
Self-reported Severity of Low Back Pain (Changes Over Time and Differences Between Groups)
Scores on a scaleExosuitControl
Baseline1.8 ± 2.61.2 ± 2.3
Survey 11.0 ± 2.01.6 ± 2.6
Survey 21.3 ± 2.31.7 ± 2.3
Survey 30.9 ± 1.91.1 ± 2.1
Survey 41.0 ± 2.21.5 ± 2.2
SecondarySelf-reported Intensity of Global Pain (Changes Over Time and Differences Between Groups)

Beyond low back pain, participants will report on total body discomfort and the intensity of discomfort at various joints: Total body discomfort and interference will be evaluated using the Pain, Enjoyment of Lift and General Activity (PEG) 3 Scale, which ranges from 0-10. A higher score indicates greater pain intensity and greater interference with enjoyment of life and everyday activity.

Time frame:
Baseline, Months (1-4)
Reported as:
Mean · Scores on a scale
Self-reported Intensity of Global Pain (Changes Over Time and Differences Between Groups)
Scores on a scaleExosuitControl
Baseline1.9 ± 2.21.6 ± 2.0
Survey 11.5 ± 2.21.8 ± 2.3
Survey 21.3 ± 2.11.9 ± 2.5
Survey 31.0 ± 2.11.5 ± 2.1
Survey 41.2 ± 2.21.4 ± 2.1
SecondarySelf-reported Intensity of Localized Body Discomfort (Changes Over Time and Differences Between Groups)

The Cornell MSD scale (reference in outcome 1) will also be evaluated at every other body part (for example, ankles, knees, hip, upper back, neck, shoulders, elbows, and wrists). The composite score represents the sum (total) of all scores across 9 body parts, and ranges from 0-810. A higher score indicates higher intensity, and frequency of work interfering discomfort for multiple body parts.

Time frame:
Baseline, Months (1-4)
Reported as:
Mean · Scores on a scale
Self-reported Intensity of Localized Body Discomfort (Changes Over Time and Differences Between Groups)
Scores on a scaleExosuitControl
Baseline20.9 ± 30.415.7 ± 20.6
Survey 112.7 ± 23.416.6 ± 24.6
Survey 211.8 ± 21.520.7 ± 35.9
Survey 314.5 ± 37.415.3 ± 20.3
Survey 417.1 ± 34.115.3 ± 21.6
SecondarySelf-reported Perception of Effort (Changes Over Time and Differences Between Groups)

A modified BORG scale has been developed with questions focusing on perceived level of back exertion. The scale ranges from 0-100, where a higher score indicates higher perceived back effort (maximal effort).

Time frame:
Baseline, Months (1-4)
Reported as:
Mean · Scores on a scale
Self-reported Perception of Effort (Changes Over Time and Differences Between Groups)
Scores on a scaleExosuitControl
Baseline50.7 ± 17.251.7 ± 18.6
Survey 146.5 ± 19.954.1 ± 20.3
Survey 244.8 ± 20.251.1 ± 24.6
Survey 342.6 ± 20.145.9 ± 19.6
Survey 446.8 ± 19.938.0 ± 18.0
SecondarySelf-reported Perception of Physical Fatigue (Changes Over Time and Differences Between Groups)

A modified BORG scale has been developed with questions focusing on perceived level of workplace fatigue. The scale ranges from 0-100, where a higher score indicates higher perceived physical fatigue (absolutely exhausted).

Time frame:
Baseline, Months 1-4
Reported as:
Mean · Scores on a scale
Self-reported Perception of Physical Fatigue (Changes Over Time and Differences Between Groups)
Scores on a scaleExosuitControl
Baseline49.8 ± 18.648.4 ± 23.5
Survey 134.8 ± 22.738.9 ± 23.5
Survey 237.3 ± 20.840.8 ± 23.1
Survey 335.5 ± 22.042.4 ± 23.6
Survey 440.1 ± 24.634.3 ± 18.9

Adverse events

Collected over From randomization until the final survey (approximately 21.5+/-1 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exosuit0/64 (0%)1/64 (1.6%)50/64 (78.1%)
Control0/31 (0%)2/31 (6.5%)20/31 (64.5%)
Most frequent serious events
Most frequent serious events
EventExosuitControl
Unrelated eventGeneral disorders1/642/31
Most frequent other events
Most frequent other events
EventExosuitControl
Dermatological and Cutaneous IssuesSkin and subcutaneous tissue disorders44/6415/31
Balance DisruptionInjury, poisoning and procedural complications29/648/31
Work Interfering Body DiscomfortInjury, poisoning and procedural complications6/645/31

Baseline characteristics

Total enrollment was 97. Two were excluded. Ninety-five were analyzed at baseline.

Age, Continuous
Age, Continuous(years)ExosuitControlTotal
Mean36 ± 12.2135.81 ± 12.3935.89 ± 12.21
Sex: Female, Male
Sex: Female, Male(Participants)ExosuitControlTotal
Female241034
Male402161
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ExosuitControlTotal
American Indian or Alaska Native123
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American17724
White422163
More than one race314
Unknown or Not Reported101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ExosuitControlTotal
Hispanic or Latino729
Not Hispanic or Latino572986
Unknown or Not Reported000
History of Low Back Pain
History of Low Back Pain(Participants)ExosuitControlTotal
Yes15722
No492473
Job Tenure
Job Tenure(Participants)ExosuitControlTotal
New Hire325
Not New Hire612990
08

Study locations

1 site
  • Undisclosed Location
    Louisville, Kentucky 40165, United States
09

References and documents

Publications

  • Quirk DA, Chung J, Schiller G, Cherin JM, Arens P, Sherman DA, Zeligson ER, Dalton DM, Awad LN, Walsh CJ. Reducing Back Exertion and Improving Confidence of Individuals with Low Back Pain with a Back Exosuit: A Feasibility Study for Use in BACPAC. Pain Med. 2023 Aug 4;24(Suppl 1):S175-S186. doi: 10.1093/pm/pnad003. PubMed 36794907 ↗
  • Zelik KE, Nurse CA, Schall MC Jr, Sesek RF, Marino MC, Gallagher S. An ergonomic assessment tool for evaluating the effect of back exoskeletons on injury risk. Appl Ergon. 2022 Feb;99:103619. doi: 10.1016/j.apergo.2021.103619. Epub 2021 Nov 2. PubMed 34740072 ↗
  • Hedge A, Morimoto S, McCrobie D. Effects of keyboard tray geometry on upper body posture and comfort. Ergonomics. 1999 Oct;42(10):1333-49. doi: 10.1080/001401399184983. PubMed 10582503 ↗
  • Baldassarre A, Lulli LG, Cavallo F, Fiorini L, Mariniello A, Mucci N, Arcangeli G. Industrial exoskeletons from bench to field: Human-machine interface and user experience in occupational settings and tasks. Front Public Health. 2022 Nov 21;10:1039680. doi: 10.3389/fpubh.2022.1039680. eCollection 2022. PubMed 36478728 ↗
  • Quirk DA, Hess A, Taylor S, Williams DOR, Pohlig R, Dalton D, Awad L, Jacobs JV, Walsh C. Moderate exosuit use reduces the incidence of back discomfort in logistic warehouse workers: a randomised controlled trial with an exploratory dose-stratified analysis. Ergonomics. 2026 Oct 15:1-20. doi: 10.1080/00140139.2026.2742501. Online ahead of print. PubMed 42878865 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data collected in this study are part of the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative. As part of the Back Pain Consortium (BACPAC) data form this study will be submitted to the Data Integration, Algorithm Development and Operations Management Center (DAC) following study completion. Researchers will have the possibility to request data from the DAC.

Time frame: Data will be uploaded to the DAC approximately 6 months to 1 year at study completion. Data may be stored in the DAC indefinitely.

Access criteria: Formal approval from the BACPAC DAC.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Apr 2025, 26 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2024 → Apr 2025 and completion Sep 2024 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2023
First posted
Apr 7, 2023
StartActual
Feb 8, 2023
Primary completionActual
Apr 26, 2025was Sep 2024
CompletionActual
Apr 26, 2025was Sep 2024
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 14, 2026
Results
Results posted
posted Oct 14, 2026
Primary completion
Sep 2024→Apr 26, 2025 (actual)
Oct 14, 2026
Study completion
Sep 2024→Apr 26, 2025 (actual)
Oct 14, 2026
Enrollment
300 (estimated)→97 (actual)
Oct 14, 2026
Primary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedLevel of workWork-interfering low back painLow Back Pain (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
  • EditedSelf-reported incidenceIncidence of low back painLow Back Pain (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4) → Months (1-4)
  • RemovedWorkplace reported incidence of a low back injury (differences between groups)Time frame: Continuously from randomization to 4 months
Oct 14, 2026
Secondary outcomes
5 edited, 1 removed
What changed in the outcomes
  • EditedSelf-reported severitySeverity of low back painLow Back Pain (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
  • EditedWorkplace Self-reported severityIntensity of low back painGlobal Pain (differences between groupsChanges Over Time and Differences Between Groups)Time frame: Continuously from randomization to 4 months → Baseline, Months (1-4)
  • EditedSelf-reported intensityIntensity of global painLocalized Body Discomfort (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
  • EditedSelf-reported intensityPerception of localized body discomfortEffort (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
  • EditedSelf-reported perceptionPerception of physical fatiguePhysical Fatigue (Changes Over Time and effort (changes over time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4) → Baseline, Months 1-4
  • Removedother outcomePerceived intervention satisfaction, job productivity, device usability, and device adverse events (changes over time and differences between groups)Time frame: Baseline, Months (1-4)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrolling by invitation→Completed
    Results posted
    Primary completion Sep 2024→Apr 26, 2025 (now actual)
    Study completion Sep 2024→Apr 26, 2025 (now actual)
    Enrollment 300 (estimated)→97 (actual)
    Primary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedLevel of workWork-interfering low back painLow Back Pain (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
    • EditedSelf-reported incidenceIncidence of low back painLow Back Pain (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4) → Months (1-4)
    • RemovedWorkplace reported incidence of a low back injury (differences between groups)Time frame: Continuously from randomization to 4 months
    Secondary outcomes 5 edited, 1 removed
    What changed in the outcomes
    • EditedSelf-reported severitySeverity of low back painLow Back Pain (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
    • EditedWorkplace Self-reported severityIntensity of low back painGlobal Pain (differences between groupsChanges Over Time and Differences Between Groups)Time frame: Continuously from randomization to 4 months → Baseline, Months (1-4)
    • EditedSelf-reported intensityIntensity of global painLocalized Body Discomfort (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
    • EditedSelf-reported intensityPerception of localized body discomfortEffort (changes over timeChanges Over Time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4)
    • EditedSelf-reported perceptionPerception of physical fatiguePhysical Fatigue (Changes Over Time and effort (changes over time and differences between groupsDifferences Between Groups)Time frame: Baseline, Months (1-4) → Baseline, Months 1-4
    • Removedother outcomePerceived intervention satisfaction, job productivity, device usability, and device adverse events (changes over time and differences between groups)Time frame: Baseline, Months (1-4)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05802914
Lead sponsor
Wyss Institute at Harvard University
Responsible party
David Adam Quirk (Principal Investigator, Harvard University) — Principal investigator
First posted
Apr 7, 2023
Start date
Feb 8, 2023
Primary completion
Apr 26, 2025
Completion
Apr 26, 2025
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion